SUTRO BIOPHARMA INC.

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

02 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

08 May 2025 13:31:42 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

01 May 2025 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

28 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

15 Mar 2025 15:40:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

13 Mar 2025 13:07:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

13 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

03 Mar 2025 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

07 Jan 2025 13:05:03 By Nasdaq GlobeNewswire

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

07 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

10 Dec 2024 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

13 Nov 2024 13:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10 Oct 2024 13:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Sep 2024 13:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

14 Sep 2024 00:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

11 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

22 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 Aug 2024 13:30:00 By Nasdaq GlobeNewswire